Novo Nordisk’s Etavopivat Hits Phase 3 Goals in Sickle Cell Disease, Regulatory Filing Planned for Late 2026
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novo Nordisk ( (NVO) ) has shared an update.
On 20 April 2026, Novo Nordisk reported topline phase 3 results from its pivotal HIBISCUS trial of once‑daily oral etavopivat in adolescents and adults with sickle cell disease, showing the drug met both co‑primary endpoints versus placebo. Etavopivat cut the annualised rate of vaso‑occlusive crises by 27%, nearly doubled the median time to first crisis, and drove haemoglobin responses in almost half of treated patients while appearing well tolerated, positioning the first‑in‑class pyruvate kinase‑R activator as a potentially transformative therapy in a field with limited options, and setting up a planned regulatory filing in the second half of 2026 that could further diversify Novo Nordisk’s portfolio beyond diabetes and obesity into rare blood disorders.
The company highlighted additional exploratory data indicating reduced need for blood transfusions and reiterated its commitment to improving access and health equity for the roughly 8 million people living with sickle cell disease worldwide. With FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations and similar orphan status in Europe, etavopivat strengthens Novo Nordisk’s presence in high‑value specialty indications, supporting its long‑term growth strategy and potentially reshaping standards of care in sickle cell disease if regulatory approvals and broader clinical data confirm these results.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, best known for its therapies targeting serious chronic diseases such as diabetes. The group employs about 68,800 people, markets its products in roughly 170 countries and is listed in Copenhagen and on the New York Stock Exchange through ADRs, underlining its scale and international investor base.
Average Trading Volume: 22,793,957
Technical Sentiment Signal: Sell
Current Market Cap: $176.8B
See more data about NVO stock on TipRanks’ Stock Analysis page.
